TLR2/4 are dominant in gastrointestinal cancers, like esophageal cancer, GC, and colon cancer, while TLR9 signaling is more common in other kinds of cancers, like breast cancer, prostate cancer, and renal cell carcinoma (34). This evidence concerns the gene TLR9 and renal cell carcinoma.